Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG200745 PPA in Refractory Myelodysplastic Syndrome
NCT02737462Phase 2Active, not recruiting
- Sponsor
- Crystal Genomics
- Start
- Jun 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivaltinostat in myelodysplastic syndrome (MDS), sponsored by Crystal Genomics. Primary endpoint: Overall Response Rate. Started Jun 2016; status: active, not recruiting.
02
Drugs
ivaltinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02737462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737462.